2-(5-Bromo-pyridin-3-yl)-2-phenyl-ethylamine | 882170-64-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-(5-Bromo-pyridin-3-yl)-2-phenyl-ethylamine
• 英文别名: 2-(5-Bromopyridin-3-yl)-2-phenylethanamine
• CAS: 882170-64-1
• 化学式: C₁₃H₁₃BrN₂
• 分子量: 277.164
• InChiKey: VVHKVFAKAGKVLD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(5-Bromo-pyridin-3-yl)-2-phenyl-ethylamine 在 palladium diacetate 、 三(邻甲基苯基)磷 、 三氟乙酸 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 10.0h， 生成 2-Phenyl-2-[5-((E)-2-pyridin-4-yl-vinyl)-pyridin-3-yl]-ethylamine
  参考文献：
  名称：

  Discovery of trans-3,4′-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation

  摘要：

  A novel series of Akt/PKB inhibitors derived from a screening lead (1) has been prepared. The novel trans-3,4'-bispyridinylethylenes described herein are potent inhibitors of Akt/PKB with IC50 values in the low double-digit nanomolar range against Akt1. Compound 2q shows excellent selectivity against distinct families of kinases such as tyrosine kinases and CAMK, and displays poor to modest selectivity against closely related kinases in the AGC and CMGC families. The cellular activities including inhibition of cell growth and phosphorylation of downstream target GSK3 are also described. The X-ray structure of compound 2q complexed with PKA in the ATP binding site was determined. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.12.017
• 作为产物：
  描述：

  3,5-二溴吡啶 在 硼烷四氢呋喃络合物 、 sodium hydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 2-(5-Bromo-pyridin-3-yl)-2-phenyl-ethylamine
  参考文献：
  名称：

  Discovery of trans-3,4′-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation

  摘要：

  A novel series of Akt/PKB inhibitors derived from a screening lead (1) has been prepared. The novel trans-3,4'-bispyridinylethylenes described herein are potent inhibitors of Akt/PKB with IC50 values in the low double-digit nanomolar range against Akt1. Compound 2q shows excellent selectivity against distinct families of kinases such as tyrosine kinases and CAMK, and displays poor to modest selectivity against closely related kinases in the AGC and CMGC families. The cellular activities including inhibition of cell growth and phosphorylation of downstream target GSK3 are also described. The X-ray structure of compound 2q complexed with PKA in the ATP binding site was determined. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.12.017

文献信息

• SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1966141A1

  公开（公告）日：2008-09-10
• [EN] SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS<br/>[FR] HETEROCYCLES A SIX ELEMENTS UTILES EN TANT QU'INHIBITEURS DE SERINE PROTEASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2007070818A1

  公开（公告）日：2007-06-21

  [EN] The present invention provides compounds of Formula (I), or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, R³ and R¹¹ are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
  [FR] La présente invention concerne des composés de formule (I) ou un stéréoisomère, un tautomère, ou un sel ou solvate pharmaceutiquement acceptable de ces composés, les variables A, B, R³ et R¹¹ étant telles que définies dans le présent document. Les composés de formule (I) sont utiles en tant qu'inhibiteurs sélectifs d'enzymes sérine protéase du système de coagulation en cascade et/ou d'activation de contact ; par exemple thrombine, facteur Xa, facteur XIa, facteur IXa, facteur VIIa et/ou kallikréine plasmique. L'invention concerne en particulier, des composés inhibiteurs sélectifs du facteur XIa ou inhibiteurs doubles du facteur XIa et de la kallikréine plasmique. Elle concerne également des compositions pharmaceutiques contenant ces composés et des procédés de traitement de troubles thromboemboliques et/ou inflammatoires au moyen de ces composés.